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ABSTRACT
Ten-eleven translocation (TET) enzymes are frequently deregulated in cancer, 
but the underlying molecular mechanisms are still poorly understood. Here we report 
that TET2 shows frequent epigenetic alterations in human glioblastoma including DNA 
hypermethylation and hypo-hydroxymethylation, as well as loss of histone acetylation. 
Ectopic overexpression of TET2 regulated neural differentiation in glioblastoma cell 
lines and impaired tumor growth. Our results suggest that epigenetic dysregulation 
of TET2 plays a role in human glioblastoma.
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INTRODUCTION
The methylcytosine dioxygenase TET2 is a member 
of the TET (ten-eleven translocation) gene family. Initially, 
this family of enzymes was proposed to be involved in 
DNA demethylation in mammals because they are able 
to catalyze the conversion of 5-methylcitosine (5 mC) in 
5-hydroxymethylcitosine (5 hmC) [1]. This is an oxidative 
reaction that requires 2-oxoglutarate- (2-OG) and Fe(II) 
as cofactors. All TET proteins can further oxidize 5 
hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) [2]. In addition to its possible role in active DNA 
demethylation, 5 hmC has also recently been proposed 
as an epigenetic mark in its own right, and having a 
functional role in chromatin regulation and epigenetic 
maintenance [3]. TET protein activity and 5 hmC profiles 
are involved in many biological processes such as, among 
others, gene transcription, DNA regulation, tumorigenesis 
and cell function, development and differentiation. 
The recruitment of TET2 to DNA and its activity 
is regulated by several factors. TET2 DNA binding sites 
are associated with IDAX, and is also related to TET2 
repression [4]. It is also known that this enzyme can be 
externally modulated by other genes, such as Wilms’ tumor 
1 gene (WT1) [5, 6], elements such as the microRNA miR-
22 [7], and, in a site-specific manner, it is mediated by 
transcription factors such as EBF1 (early B-cell factor 1) 
[8] among others. 
TET2 activity is involved in many of the biological 
processes, including the embryogenesis. During zygote 
formation, expression of TET2 is low, but levels 
increase in the blastocyst stage and during germ layer 
differentiation. Alterations in embryonic development 
and cell differentiation process [9, 10], especially in 
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hematopoietic lineages [11, 12], have been identified in 
different TET2 deficient mice models. TET2 expression 
levels are tissue dependent, and the consistent expression 
found mainly in hematopoietic [13, 14] and neural lineages 
[15–17] in adults, highlights the special importance that 
TET2 probably plays in these tissues. 
TETs are dysregulated in a number of pathological 
processes. Aberrant 5 hmC patterns are common in certain 
tumor types [18, 19], and TET2 has been described as a 
tumor suppressor gene in many cancers [20, 21]. TET2 
downregulation has been studied in a large range of 
hematological malignances, with various mutations in 
the gene having been indicated as the principal cause 
[13, 22, 23]. However, in other cases, TET2 activity 
decreases as result of mutations in or disorders of other 
enzymes such as isocitrate dehydrogenase (IDH) [24]. 
TET2 dysregulation is also present in other tumor types 
[25–27], in some of which TET2 downregulation has been 
found to be associated with poor prognosis and reduced 
patient survival [28–30].
Despite the large numbers of studies carried out the 
mechanisms that generate this loss of TET2 protein in 
some tumors is not yet clearly understood. Here we show 
that epigenetic mechanisms might play an important role 
in the aberrant regulation of TET2 in human glioma.
RESULTS
Frequent epigenetic dysregulation of TET2 
hydroxymethylation in human glioblastoma 
To study the possible aberrant epigenetic regulation 
of TET2 in brain tumors, we first used data from the 450K 
Infinium Illumina methylation platform. We determined 
the DNA methylation and hydroxymethylation status of 
21 CpG positions within TET2 promoter DNA regions and 
the gene body in 9 samples obtained from patients with 
glioblastoma and 5 from non-tumorigenic brain samples. 
This revealed a locus-specific pattern of DNA methylation 
and hydroxymethylation alterations in tumoral samples 
(Figure 1A). CpG sites located at the promoter CpG island 
presented very low levels of 5 mC and of 5 hmC in both 
brain and glioblastoma samples. In contrast, intragenic 
CpG sites presented much higher 5 hmC levels in the non-
tumorigenic samples compared with those from tumors 
(on average, 15% and 2%, respectively), while intragenic 
5 mC levels were higher (10%) in tumoral samples. 
To validate the data obtained with the methylation 
arrays we used bisulfite pyrosequencing to analyze the 
DNA methylation and hydroxymethylation status of 
two CpG sites located at intron 2 of TET2 (cg12306086 
and cg20586654) in the same samples analyzed in the 
methylation arrays, as well as in additional glioblastoma cell 
lines (see material and methods). The results confirmed the 
5 mC and 5 hmC profiles obtained in the arrays (Figure 1B–
1C). Moreover, these experiments revealed a similar pattern 
of 5 mC and 5 hmC at two neighboring CpG sites of the 
cg12306086 position (Supplementary Figure 1A). The 
loss of 5 hmC in glioblastoma was further validated by the 
results of an alternative technique which is not dependent 
on the oxidative bisulfite conversion and based instead on 
DNA immunoprecipitation with an antibody against 5 hmC 
(Supplementary Figure 2).
Next, we used bisulfite pyrosequencing to analyze the 
5 mC and 5 hmC levels at the cg20586654 CpG position 
in an independent cohort of 8 glioblastomas and 7 non-
tumorigenic brains. We detected TET2 hypermethylation 
and hypo-hydroxymethylation in all the tumoral samples 
analyzed (Supplementary Figure 1B), which confirmed that 
this is a frequent event both in vivo and in vitro.
To identify other possible epigenetic mechanisms 
involved in TET2 regulation, we carried out quantitative 
ChIP analyses  on brain and glioma samples using an 
antibody against H4K16 acetylation, a histone post-
translational modification associated with gene activation 
[31]. We found a decrease in H4K16ac in the tumoral 
sample (Supplementary Figure 3), further supporting 
the idea that, in addition to DNA methylation and 
DNA hydroxymethylation, histone post-translational 
modifications could have an important role in TET2 
regulation in glioma.
Epigenetic dysregulation is associated with TET2 
repression in glioblastoma
To determine the possible role of TET2 epigenetic 
dysregulation in gene expression, we first compared the 
mRNA expression level of TET2 in 14 non-tumorigenic 
brain samples, 7 samples obtained from patients with 
glioblastoma multiforme and 4 glioblastoma cell lines. 
TET2 expression was lower in primary glioblastomas and 
glioblastoma cell lines than in control samples (Wilcoxon 
rank sum test, p-value < 0.05 for cell lines) (Figure 2A). 
However, in all the glioblastoma cancer lines analyzed, 
TET2 expression was only just above detectable levels 
(Figure 2A). In the same vein, TET2 protein expression 
was stronger in the control brain samples than in primary 
glioblastoma samples (Figure 2B).
Ectopic overexpression of TET2 reduces cell 
growth in vitro
We next wanted to determine whether TET2 
inactivation blocked cell growth suppression in brain 
malignancies which displayed TET2 epigenetic-associated 
downregulation. To address this issue, we transfected 
TET2 in the glioblastoma cell line LN229, which exhibits 
hypo-hydroxymethylation as well as downregulation of 
TET2 mRNA (Figure 3). TET2 transfection resulted in the 
upregulation of TET2 mRNA (Wilcoxon rank sum test, 
p-value < 0.05) (Figure 3A) and protein levels (Figure 3B). 
Impedance-based cellular growth assays revealed that 
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Figure 1: Locus specific TET2 alterations of DNA methylation and hydroxymethylation in glioma. (A) Schematic 
representation of gene organization. Exons, introns, and transcription start site (TSS) locations are shown below. The 21 CpG positions 
along TET2 analyzed in the Illumina methylation array are indicated by black dots (intragenic CpG sites are bounded by the orange frame). 
Locus-specific patterns of DNA methylation (blue to yellow) and hydroxymethylation (gray to blue) in 5 non-tumorigenic human brain 
and 9 glioblastoma samples are shown. Location of representative CpGs selected for study (cg12306086 and cg20586654) are indicated 
by the small red boxes below the heatmap, in which they are marked with asterisks. (B) Box plot showing differences between the average 
percentage of 5 mC and 5 hmC in both normal brain and glioma samples of the two-representative intragenic CpGs studied (cg12306086 
and cg20586654) (upper part). Technical validation by bisulfite pyrosequencing of 5 mC and 5 hmC changes occurring among normal 
samples (n = 5), primary tumors (n = 9) and glioblastoma cell lines (n = 4) are shown below. p-values were adjusted by applying the 
Bonferroni correction. *p-value < 0.05; **p-value < 0.01. (C) Scatter plots showing the percentage of 5 mC (upper panel) and 5 hmC (lower 
panel) in normal (blue plots) and tumoral (yellow plots) samples obtained by pyrosequencing (y-axis) and arrays (x-axis). ρ: Spearman 
rank correlation. 
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TET2-transfected cells (two clones) grew slightly less than 
the control cells (Wilcoxon rank sum test, p-value < 0.05 
in both clones) (Figure 3C) as well as finding significant 
differences in population doubling time and slope between 
control and TET2-overexpressing clones (General linear 
models p-value < 0.01 in both clones) (Figure 3C). In 
addition, overexpression of TET2 resulted in a decrease 
in cell viability (General linear model, p-value < 0.05) 
(Figure 3D). 
TET2 expression is associated with glioblastoma 
growth in vivo
To study the effect of TET2 expression in 
glioblastoma in vivo we tested the ability of TET2-
transfected LN229 cells to form tumors in nude mice 
as compared with control cells transfected with an 
empty vector (Figure 4A). Negative control of LN229 
glioblastoma cells resulted in tumors with exponential 
growth (Figure 4A). In contrast, two clones of LN229 
cells which overexpress TET2 (Figure 3A, Supplementary 
Figure 4) had much lower tumorigenic potential 
(Figure 4A). Mice were sacrificed 72 days after tumor-
xenograft implantation. At that time, tumors are around 
two times larger in mice xenografted with cells transfected 
with the empty vector than in mice transfected with cells 
overexpressing TET2 (Linear model, p-value < 0.05) 
(Figure 4A). Tumor weight was also notably different 
between the two clones and the scramble (Linear model, 
p-value < 0.005) (Figure 4B).
TET2 regulates neural differentiation in 
glioblastoma cells
The effect of TET2 overexpression on glioblastoma 
cell growth and viability, together with previous reports 
suggesting that this enzyme plays an important role 
in neural differentiation [32–34] led us to postulate 
the hypothesis that the antitumoral effect of TET2 in 
brain tumors is mediated, at least in part, by its role in 
this process. To address this issue, we used a Neural 
Lineage Profiler assay to compare the relative expression 
of more than 92 markers of different stages of human 
neuroectodermal differentiation between control and 
TET2-transfected LN229 cells (Supplementary Table 1). 
Results showed that TET2 upregulation consistently 
altered the expression of 19 neuroectodermal markers 
in both TET2 clones (Figure 5, Supplementary Table 1). 
The greatest changes were observed for the Proneural 
transcriptor factor/Neural and Oligodendrocyte precursor 
Mash1 [35] and Cystathionine β-synthase (cbs), 
an enzyme with high expression levels in astrocyte 
lineages [36].
DISCUSSION
The tet methylcytosine dioxygenase 2 (TET2), 
as well as its homologues TET1 and TET3, catalyze 
the conversion of the epigenetic chemical modification 
5-methylcytosine (5 mC) into 5-hydroxymethylcytosine 
(5 hmC), which is subsequently oxidized and is converted 
Figure 2: TET2 expression is downregulated in glioma. (A) Comparison of TET2 mRNA expression levels between control 
brains (n = 14), gliomas (n = 7) and glioblastoma cell lines (n = 4) are shown on the left. Expression levels were determined by qRT-PCR, 
and data are expressed as a ratio in relation to GAPDH. Fold change was calculated relative to control samples with low expression levels. 
Wilcoxon signed rank test was applied. **p-value < 0.01. (B) TET2 protein levels detected by immunohistochemistry (IHC) are shown. 
Oncotarget25926www.oncotarget.com
into 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) [2]. This knowledge initially led to the notion 
that TET enzymes play an important role in active DNA 
demethylation [37, 38]. However, recent studies showing 
that 5 hmC might be an epigenetic mark in its own right 
suggest that the role of TET enzymes is not simply 
restricted to actively demethylating genomic DNA [3, 39].
An especially high expression of TET2 has 
been found in hematopoietic tissues [40] suggesting it 
has an important role to play in this process, which is 
supported by the fact that TET2 is frequently mutated in 
hematological malignancies [41–43]. 
Although at lower frequencies than observed in 
hematological malignancies, TET2 alterations have also 
been found in various types of solid tumors, such as renal 
cell carcinoma [44], metastatic castration-resistant prostate 
cancer (mCRPC) [45], lung [46], colon and rectal cancer 
[47]. However, these mutations cannot always explain 
Figure 3: In vitro effects of TET2 restoration in LN229 glioblastoma cell line. (A) qRT-PCR of TET2 transfected variant 1 
in two clones of LN229. Expression levels were determined by real time-PCR and data, are expressed as a ratio with respect to GAPDH. 
Fold change was calculated relative to scramble. (B) WB analysis against TET2 in the same LN229 clones. Ratios between TET2 and 
β-actin intensity values calculated with ChemiDoc™ XRS+ software are shown. (C) Proliferation rate was represented as cell index units. 
The graphic shows average and standard deviation of two technical replicates of each clone over 135 hours. Slope (1/hours) and doubling 
time (hours), analyzed during the exponential growth phase (15–72 h), is also shown (right panels). (D) Cell viability was determined by 
MTT assay on scramble and TET2-stably transfected cells. The average absorbance in six replicates at various time points, normalized with 
respect to the average absorbance at time 0 h for each sample, are represented. Wilcoxon signed rank test and general linear models were 
applied and p-values were adjusted applying the Bonferroni correction. *p-value < 0.05; ***p-value < 0.001.
Oncotarget25927www.oncotarget.com
the frequently altered expression of this protein in cancer 
[19, 48, 49]. Interestingly, although TET2 is not frequently 
mutated in glioblastoma [50–52], it has been found to be 
frequently downregulated [53]. 
To identify alternative molecular mechanisms 
involved in TET2 downregulation in glioblastoma we 
considered the possible role of epigenetic factors by 
analyzing the TET2 promoter and intergenic levels of 5 mC, 
5 hmC and H4K16ac in control and tumoral samples. Our 
results demonstrated that there were alterations of all the 
epigenetic marks analyzed.  
At a functional level, the restoration of TET2 
activity in the LN229 glioblastoma cell line reduced cell 
proliferation in vitro, and tumor growth in vivo, which is 
Figure 4: Antitumoral effects of TET2 restoration on tumor growth in vivo. (A) Scramble (on left, represented in red) and 
TET2 transfected LN229 cells (TET2 # 15 on right, in green, and TET2 # 25 on neck base, in blue) were s.c. injected into nude mice 
(n = 5) (representative image on the left). Evolution of tumor growth was measured regularly for 72 days. Statistically significant differences 
in tumor growth (A) and weight (B) were shown at the endpoint. General linear models were applied, and p-values were adjusted applying 
the Bonferroni correction. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001. 
Figure 5: Regulation of neural-lineage markers is associated with TET2 restoration. mRNA expression of 92 neural related 
genes was analyzed with the neural lineage qPCR Profiler Kit (System Biosciences). TET2 clones were compared with scramble. For 
both clones, the heatmap representation includes genes with at least 2-fold expression changes (overexpression log2 ≥ 1, green scale; 
downregulation log2 ≤ –1, red scale).
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in agreement with previous work suggesting that TET2 
has antitumor activity in leukemias [21, 54] and in other 
types of tumors including parathyroid carcinoma [55], 
colorectal cancer [20] and glioma [53]. These results, 
then, suggest that TET2 activity is frequently disrupted in 
cancer through different molecular mechanisms and that 
this process might contribute to malignant transformation.
Our results show that restoration of TET2 
expression in glioblastoma cells tends to upregulate genes 
involved in neural differentiation including the Brain 
fatty acid-binding protein (BFABP), implicated in glial 
lineage differentiation [56], the proneural basic helix–
loop–helix (bHLH) transcription factor Mash1, related to 
oligodendrogenesis and neural precursor differentiation 
[57–61] and Cystathionine β-Synthase (cbs), whose 
protein expression is detected at high levels in astrocytes 
[62]. Interestingly, low expression of cbs was found in 
gliomas [63]. These results therefore suggest that TET2 
might be involved in neural differentiation, which is in 
line with previously published data [32, 64, 65].
It has previously been shown that MicroRNAs 
(miRNAs) play an important role in neuronal development 
and neurogenesis [66, 67]. We also detected changes 
in neuron-specific microRNA miR-124 [66] and 
oligodendrocyte-specific microRNA miR-338 [67] 
expression when TET2 activity is restored in LN229 
glioblastoma cell line. In contrast, neural progenitor 
markers of early stages of differentiation were slightly 
downregulated as Sox2 [68, 69]. These results are in 
agreement with previous data suggesting that TET2 plays 
an important role in neural development [17, 33, 70, 71] 
and support the notion that the antitumoral effect of TET2 
in glioblastoma might be mediated, at least in part, through 
its role in the regulation of neuroectodermal differentiation. 
MATERIALS AND METHODS
Human cell lines and human samples
The human glioblastoma cell lines (LN229, LN-18, 
T98-G and U-87 MG) were cultured according to American 
Type Culture Collection (ATCC) recommendations and 
authenticated using short tandem repeat profiling of 
an extracted DNA sample employing an AmpFℓSTR 
Identifiler for high resolution screening and intraspecies 
cross-contamination detection (Bio-Synthesis, Inc). Cell 
lines were cultured in our laboratory at 37º C in 5% CO2 
in Dulbecco´s Modified Eagle´s Medium (DMEM) (Gibco, 
41965) supplemented with 10% fetal bovine serum (FBS) 
(F6178, Sigma), 2% penicillin/streptomycin (Gibco, 15070) 
and 1% Amphotericin B (Gibco, 15290). 
Healthy human biopsy (n = 5) and tumor samples 
(n = 11) were obtained from the Institute of Oncology of 
Asturias Tumor Bank (Asturias, Spain). Histopathological 
study had previously been confirmed at the Hospital 
Universitario Central de Asturias, and informed consent 
was obtained from all patients before sample collection. 
Samples were frozen at –80° C until further analysis. A 
second group of donated samples came from The Banc 
De Teixits Neurològics-Biobanc Hospital Clínic-IDIBAPS 
(Barcelona, Spain) and The Biobanco Hospital Virgen de 
la Salud (Toledo, Spain). Tissue collection and all analyses 
were approved by the appropriate institutional review 
boards in accordance with national and EU guidelines.
DNA methylation analysis with high-density 
array
Microarray-based DNA methylation profiling was 
performed on 5 healthy samples and 9 tumoral samples 
using the HumanMethylation 450 BeadChip array [72]. 
Oxidative bisulfite (oxBS) and bisulfite-only (BS) conversion 
was performed using the TrueMethyl® protocol for 450K 
analysis (Version 1.1, CEGX) following the manufacturer’s 
recommended procedures. Processed DNA samples were 
then hybridized to the BeadChip (Illumina), following the 
Illumina Infinium HD Methylation Protocol. Genotyping 
services were provided by the Spanish Centro Nacional de 
Genotipado (CEGEN-ISCIII) (www.cegen.org).
Raw IDAT files were processed using the R/
Bioconductor package minfi [73] (version 1.14.0), 
implementing the SWAN algorithm [74] to correct for 
differences in microarray probe design. Probes where 
at least two samples had detection p-values > 0.01, 
and samples where at least 5500 probes had detection 
p-values > 0.01 were filtered out. M-values and beta values 
were then computed as the final step in the preprocessing 
procedure. In line with a previously published methodology 
[75], M-values were used for the statistical analyses and 
beta values for effect size thresholding, visualization and 
report generation.
Beta values from oxBS samples were subtracted from 
their corresponding BS treated pairs, generating an artificial 
dataset representing the level of 5 hmC for each probe and 
sample as per a previously published methodology [76]. 
One further dataset, representing 5 mC levels, was created 
using the beta values from oxBS samples. Differential 
methylation and hydroxymethylation of an individual probe 
was determined by a moderated t-test implemented in the R/
Bioconductor package limma [77].
Bisulfite pyrosequencing
The DNA methylation and hydroxymethylation 
status of representative CpG sites were evaluated in 12 
healthy and 22 tumoral samples, and in glioblastoma cell 
lines using bisulfite pyrosequencing. Genomic DNA was 
isolated following standard phenol-chloroform extraction 
protocols. Oxidative bisulfite (oxBS) and bisulfite-only 
(BS) conversion of DNA was performed following an 
adapted protocol from the TrueMethyl Array Kit User 
Guide (CEGX, Version 2). DNA samples were cleaned 
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with Agencourt AMPure XP (Beckman Coulter) and then 
oxidized using KRuO4 (Alpha Aeser) solution (375 mM 
in 0.3 M NaOH). Finally, BS conversion was carried out 
using Epitect bisulfite Kit (Qiagen). Polymerase chain 
reaction (PCR) amplification of the regions of interest 
was performed using specific primers (see Supplementary 
Table 2) designed using the software PyroMark assay 
design (v. 2.0.01.15). Pyrosequencing was conducted 
using PyroMark Q24 reagents, vacuum prep Workstation, 
equipment, and software (Qiagen).
5-hydroxymethylcytosine immunoprecipitation-
qPCR assay
Immunoprecipitation of 5 hmC was carried out using 
the EpiQuik Hydroxymethylated DNA Immunoprecipitation 
(hMeDIP) Kit (Epigentek), according to the manufacturer’s 
instructions. Input, non-specific IgG- and 5 hmC-enriched 
fractions were obtained from ten samples corresponding 
to five normal brains and five glioma tumors. All fractions 
were amplified by qPCR with oligonucleotides specific to 
the CpG position detailed in Supplementary Table 2. After 
confirming there were no significant differences between 
input DNAs, 5 hmC relative enrichment was calculated as 
a Fold Change relative to Input Ct Mean.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed with 
control brain and glioma samples. The assay was performed 
as described in the protocol “Chromatin preparation from 
tissues for chromatin immunoprecipitation (ChIP)” by 
Abcam, with some minor modifications. Frozen tissue 
was fixed for 10 min with 1–1.5% formaldehyde solution. 
Crosslinking was halted by the addition of glycine to 
125 mM. Homogenization was performed on ice using a 
Micropistille Eppendorf tightly fitted into the bottom of 
the eppendorf tube. Samples were resuspended in Lysis 
Buffer (50 mM HEPES-KOH pH7.5;140 mM NaCl; 1 mM 
EDTA pH8; 1% Triton X-100; 0.1% Sodium Deoxycholate; 
0.1% SDS; Protease Inhibitors) and sonicated. Sonication 
was performed by Diagenode’s Bioruptor® Sonicator to 
obtain chromatin fragments of 200–500 bp in length. 
Immunoprecipitations were performed overnight using 
antibodies against H4K16ac (Active Motif, 39167), with 
total histone H3 (Abcam, ab1791) as positive control, and 
IgG antiserum (Abcam, ab46540) as negative control. 
Antibody–chromatin complexes were precipitated with 
Salmon Sperm DNA/Protein A-Agarose beads (Upstate 
Biotechnologies), then washed and eluted using the 
corresponding buffer (1% SDS,100mM NaHCO3). DNA 
was extracted with phenol–chloroform and was ethanol-
precipitated. Immunoprecipitated DNA was analyzed by 
real-time PCR on TET2 promoter region (Supplementary 
Table 2) using SYBR® Green in the StepOnePlus™ Real-
Time PCR System (Applied Biosystems). All measurements 
were performed in triplicate, non-template controls were 
included, and a calibration curve was determined for each 
primer set.
qRT-PCR
Total RNA was extracted from LN229 glioblastoma 
cell line and human samples using TRIzol Reagent (Life 
Technologies). Residual genomic DNA was removed 
with DNA-free kit (Invitrogen) and cDNA synthesis was 
performed using SuperScript III reverse transcriptase 
(Invitrogen) following the manufacturer´s instructions. 
Quantitative PCR reactions were tested in triplicate using 
SYBR Green PCR Master Mix (Applied Biosystems) 
and specific primers in StepOnePlus™ Real-Time PCR 
System (Applied Biosystems). Data were analyzed by 
the double delta Ct method, and gene expression was 
normalized to glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) as endogenous control. All primers were 
acquired from Sigma. Oligonucleotide sequences are listed 
in Supplementary Table 2.
The cDNA used in the Neural Lineage qPCR Profiler 
Kit (System Biosciences) was synthesized according to 
the manufacturer´s instructions and quantitative PCR 
reactions were performed in HT7900 Real Time PCR 
System (Applied Biosystems).
Immunohistochemistry
For the immunohistochemical analysis of protein 
levels we used the EnVision FLEX Mini Kit (DAKO, 
K8024) and Dako Autostainer system. Paraffin embedded 
tissues (3–5 µm) were deparaffinized, rehydrated, and then 
epitopes were retrieved by heat induction (HIER) at 95°C 
for 20 min at pH 6 (DAKO, GV805) in the Pre-Treatment 
Module, PT-LINK (DAKO).
Sections were incubated with TET2 antibody 
(Abcam, Ab94580) diluted in EnVision™ FLEX Antibody 
Diluent (DAKO, K8006) (1:500 dilution) for 30 min after 
blocking endogenous peroxidase with EnVision™ FLEX 
Peroxidase-Blocking Reagent (DAKO, DM821). The 
signal was detected using diaminobenzidine chromogen 
as substrate after incubation with Dako EnVision™ FLEX 
/HRP (DAKO, DM822). Sections were counterstained 
with hematoxylin. Appropriate negative controls were 
also tested.
After the complete process, sections were 
dehydrated and mounted with permanent medium (Dako 
mounting medium, CS703).
TET2 transfection
LN229 cell line was transfected in order to 
overexpress TET2 (GeneCopedia, EX-H3630-M43), 
incorparating a non-effective Scramble construct as 
negative control (GeneCopedia, EX-EGFP-M43), 
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using Lipofectamine 3000 transfection Kit (Invitrogen, 
L3000015) as per the manufacturer´s recommendations. 
The cells were collected 72 h after transfection and stable 
transfectants were obtained after selection with 1 mg/ml 
G418 disulfate salt (Sigma, A-1720). TET2 expression was 
checked by qRT-PCR using the specific primers for TET2 
transcription variant1 detection (Supplementary Table 2). 
TET2 expression was confirmed in positive clones by 
Western blot (WB) using anti-TET2 antibody (1:500, 
ab1789, Abcam) and anti-β-actin (1:5000, sc-47778, Santa 
Cruz) as a loading control.
Cell growth experiments
Cell proliferation rate was measured with the 
iCELLigence real-time cell analyzer (RTCA) (ACEA 
Biosciences). Duplicates of LN229 transfected cells 
(15 × 103 cells) were seeded onto analyzer specific 
E-Plates L8. Cell impedance was measured by continuous 
monitoring every 3 hours for 6 days (135 h) through micro 
electric biosensors located at the base of the plate wells. 
Data were exported from the cell analyzer instrument to the 
control unit and RTCA software was used to analyze slope 
and doubling time parameters. As cell growth increases, 
more cells attach to the plate electrodes leading to an 
increase in the impedance measured by the instrument. 
Cell index was the parameter used to quantify the relative 
change in electrical impedance. Data were normalized after 
15 hours.
Cell viability assay
Cell viability was determined by 3-(4,5- 
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
(MTT) assay on stably transfected cells, as described by 
Mosmann and colleagues [78]. Six replicates (2 × 103 
cells) per condition and time point were established in 96-
well plates. MTT (500 µg/ml) (Sigma, M5655) was added 
to medium and kept at 37° C and 5% CO2. After 3 hours, 
the MTT was removed and the Formazan crystals formed 
were dissolved in dimethyl sulfoxide (DMSO) (100 µl/
well) (Sigma, D5879-M) and absorbance at 595 nm was 
measured with an automated microtiter plate reader.
Xenografts
Five-week old NU/NU female mice (Charles River 
Japan Inc. Kanagawa, Japan) were subcutaneously injected 
with 1 × 106 cells mixed 1:1 with BD Matrigel Matrix 
High Concentration (BD Biosciences, Erembodegem, 
Belgium) which had been previously diluted 1:1 with 
culture medium. Both, TET2 and scramble transfected 
cells were injected into five nude mice. Tumor size was 
measured with calipers twice a week and tumor volume 
was determined as V = 4/3π(Rr)2 were R is the maximum 
diameter and r is the minimum diameter. Mean tumor 
volume was calculated for the corresponding group. After 
sacrifice, the tumors were excised and weighed.
Statistical analysis
Group comparisons were performed by fitting a 
general linear model to each dataset. Contrasts were 
defined to test the different hypotheses (comparisons 
between levels of the main group variable) on each of 
the models. Repeated measures designs, involving the 
measure of a quantity across different time points, were 
modeled using a general linear model, with a main group 
predictor and a blocking variable describing the time of 
observation. Time was modeled as an ordinal variable. 
Contrasts were defined over the main group variable. 
Correlation between variables was assessed using the 
Spearman rank correlation coefficient.
The resulting p-values were adjusted using the 
Bonferroni method for controlling the Family-Wise Error 
Rate (FWER). Goodness-of-fit was assessed for each of 
the models using graphical methods and the Shapiro-
Wilk test on the residuals. A Wilcoxon rank-sum (group 
comparisons) or signed-rank (comparisons across time) 
test was used for each pairwise comparison if the residuals 
showed strong deviations from normality and there were 
enough observations.
All statistical analyses were conducted using the 
R statistical programming language (version 3.4.0) (R 
Development Core Team 2008) [79].
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